A phase 1 clinical trial evaluating SAGE-319
Latest Information Update: 15 Jan 2025
At a glance
- Drugs SAGE-319 (Primary)
- Indications Neurological disorders
- Focus Adverse reactions
Most Recent Events
- 12 Jan 2025 According to an Sage Therapeutics media release, company expects data from a Phase 1 multiple ascending dose (MAD) study by late 2025.
- 24 Feb 2023 New trial record